1-3 of 3
Jing C. Ye
Close
Sort by
Journal Articles

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

Leon Bernal-Mizrachi, Ajay K. Nooka, Leonard Heffner, Craig E. Cole, Jing C. Ye, Ravi Vij, Craig C. Hofmeister, John Rushton, Zhengjia Chen, Subir Goyal, Jeffrey M. Switchenko, Sagar Lonial, Jonathan L. Kaufman
Journal: Blood
Blood (2021) 138 (Supplement 1): 2758.
https://doi.org/10.1182/blood-2021-153922
Published: 2021
Journal Articles

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Nina Shah, Alan Tan, Elizabeth Budde, Craig C. Hofmeister, Andrew J. Cowan, Miguel-Angel Perales, Taewoong Choi, Hayder Saeed, Julio C. Chavez, Jing C. Ye, Mitchell S. Cairo, David A. Rizzieri, Gregory J. Orloff, Zachary Lee, Neha Dixit, Wildaliz Nieves, Qiang Zhao, Xiaoli Wang, Kazuharu Kai, Mario Q. Marcondes, Mary A. Tagliaferri, Jonathan Zalevsky, Krina K. Patel
Journal: Blood
Blood (2021) 138 (Supplement 1): 3134.
https://doi.org/10.1182/blood-2021-147758
Published: 2021
Journal Articles

Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Steven M. Horwitz, Tatyana A. Feldman, Jing C. Ye, Michael S. Khodadoust, Javier Munoz, Paul A. Hamlin, Youn H. Kim, Ryan A. Wilcox, Manish R. Patel, Greg P. Coffey, Muhtarjan Osman, Jaymes S Holland, Cristina B Guzman, Sonali M. Smith
Journal: Blood
Blood (2021) 138 (Supplement 1): 622.
https://doi.org/10.1182/blood-2021-148352
Published: 2021